{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoPmVlcUKDA","lastupdate":"2024-05-06T00:00:00.000Z","update_date":"2024-05-06T00:00:00.000Z","lastModified":"Sep 21, 2024","active":1,"confidence_score":90,"confidence_score_reason":"markets, not claimed","urlname":"nectin-therapeutics","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$qORXS8Vu1j2wfNA0DNbcalolIMwmIFNm8GSboiCTN6S5MF5pnyzjZA.jpeg","name":"Nectin Therapeutics","oneliner":"Next-generation Immunotherapy Agents","registrar":"515675890","website":"https://www.nectintx.com","careerspage":"","founded_month":1,"founded_year":2017,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/69206104","instagram":""},"social":["https://www.linkedin.com/company/69206104"],"flattenedsociallinks":"https://www.linkedin.com/company/69206104","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"11-50","employees_exact":11,"patent":1,"raised":36000000,"stage":"A","public_stage":"A","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Nectintx","NectinTx"],"about":"Nectin Therapeutics is a biotechnology company devoted to transforming the lives of cancer patients by the development of next-generation immune-oncology (IO) therapies.\r\n\r\nThe company is dedicated to the development of novel therapeutic options for cancer patients. It is developing a diverse pipeline of targeted antibodies based on the nectin pathways. These antibodies overcome inhibitory pathways deployed by the tumors  and allow immune cells to effectively destroy cancer cells. Additionally, based on the unique expression patterns of several nectin proteins, it develops CAR-T and -NK drivers that directly target tumor cells in various indications, including hard-to-treat cancers.\r\n\r\nThe company was established based on seminal research at the Hebrew University of Jerusalem and the University of Rijeka. Its technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies and antibody-drug-conjugates.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+972544247524","country":null,"address":{"israeli":[{"id":"6b859f7d-0f03-4b19-8c5d-d2416466b6bf","city":"Jerusalem","type":null,"address":"Givat Ram, Jerusalem, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"56979449-8337-4581-85c4-401e41d0fffa","city":"Fort Lee","address":"1 Bridge Plaza North, Fort Lee, NJ, USA","country":"United States","placeid":null}]},"headquarter_address":null,"district":"Jerusalem District","news":[{"id":"BjKbmE5SGDSxR5EC4APGro6SN0gsoCcFRHotu3QBOynI4OBTeRQFBC","date":"May 6, 2024","link":"https://en.globes.co.il/en/article-israeli-biotech-co-nectin-therapeutics-raises-10m-1001478040","source":"en.globes.co.il","visible":1,"analysis":{"tags":"Investment, Biotechnology","company":"Nectin Therapeutics","layoffs":"Not mentioned","summary":"Guangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Israeli biotechnology company Nectin Therapeutics. Nectin is developing targeted immunotherapies for resistance to approved immune oncology treatments. The investment will be used to continue the development of Nectins portfolio of novel immuno-oncology products, including the advancement of Nectins ongoing NTX1088 global Phase 1 clinical trial targeting PVR and the preclinical development of its anti-drug conjugate (ADC) portfolio.","partners":"Not mentioned","customers":"Not mentioned","investors":"Guangzhou-Israel Biotechnology Fund","confidence":9,"key_topics":["Investment","Immunotherapies","Clinical Trial","Biotechnology","Cancer Treatment"],"date_of_event":"May 6, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$10 million","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"MrWbcJ0dauHTfMy2R4wXz3WaCwpxEEujnvV4w13Yumd2duG0HxhsII","news_summary":"Israeli biotech co Nectin Therapeutics raises $10m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"DPEGOiOcUpgfNVqzWUb7iCHZX94Dw5pS36e8GFs0DVtm9SoCmdOztX","date":"May 16, 2023","link":"https://www.businesswire.com/news/home/20230516005434/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"m3gP8cQKk3MmurlhekwU2qEBQui2cnHMPNSl5DnYa3EB5U355VVZTy","news_summary":"Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin's Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"MqA4kpLb6poQ2IbpvrImUMLcb4WIzZTbvqJu3rFm5kW5uxtxs6bXTU","date":"Feb 7, 2023","link":"https://www.biospace.com/article/releases/nectin-therapeutics-to-collaborate-with-merck-on-a-clinical-trial-of-anti-pvr-antibody-ntx1088-in-combination-with-keytruda-pembrolizumab-in-patients-with-locally-advanced-and-metastatic-solid-tumors/","source":"www.biospace.com","visible":1,"analysis":{"tags":"clinical trial collaboration","company":"Nectin Therapeutics Ltd.","layoffs":null,"summary":"Nectin Therapeutics has entered into a clinical trial collaboration agreement with Merck to evaluate the safety and efficacy of its novel anti-PVR antibody, NTX1088, in combination with Mercks anti-PD1 therapy, KEYTRUDA, in patients with solid tumors. NTX1088 aims to restore the antitumor immune activity of DNAM1 by blocking PVR, a protein associated with resistance to immune checkpoint inhibitors. The phase 1 trial with NTX1088 has already been initiated. The collaboration represents a promising new therapy for cancer patients and a milestone for Nectin Therapeutics.","partners":"Merck","customers":null,"investors":null,"confidence":8,"key_topics":["Nectin Therapeutics","Merck","clinical trial collaboration","NTX1088","KEYTRUDA"],"date_of_event":"November 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"891KyGBMOwwYHnQwspsBWD85XHcd0Mb4W3GlGB3RUsc4VRRXynrFsV","news_summary":"Nectin Therapeutics to Collaborate with Merck on a Clinical Trial of Anti-PVR Antibody NTX1088 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced and Metastatic Solid Tumors | BioSpace","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2CstjLpo1h0CRtuVgi2st5hlybLDZeawXDUvp46sti9asfu5aSdo2g","date":"Dec 1, 2022","link":"https://en.globes.co.il/en/article-israeli-co-nectin-therapeutics-raises-25m-1001431433","source":"en.globes.co.il","visible":1,"analysis":{"tags":"immunotherapies","company":"Nectin Therapeutics","layoffs":null,"summary":"Nectin Therapeutics, an Israeli biotechnology company, has completed a $25 million Series A financing round led by IBF and Peregrine Ventures. The funding will be used to support the ongoing clinical evaluation of NTX1088, the companys first-in-class PVR (CD155) blocker, and to further advance its pipeline of targeted immunotherapies and Antibody Drug Conjugates (ADCs). Nectin is developing novel targeted immunotherapies to address resistance to approved immuno-oncology treatments. The company has also announced the dosing of the first patient in its Phase I clinical trial of NTX1088, which is being conducted at The University of Texas MD Anderson Cancer Center. Nectin aims to overcome the limitations of existing IO therapies and provide new treatment options for patients with difficult-to-treat cancers.","partners":null,"customers":null,"investors":"IBF, Peregrine Ventures, aMoon Fund","confidence":9,"key_topics":["Nectin Therapeutics","Series A financing","NTX1088","immunotherapies","clinical trial"],"date_of_event":"November 30, 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$25 million","structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"7uVJJJjR37VRlyLM5aDO88Cs6A1W6eYUVGeCk57oq8udb5lFiKUEp1","news_summary":"Israeli co Nectin Therapeutics raises $25m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"xMhB1Ey4eHwHJmsEOazxRLL2vxtn6wyv6Hgu6BYHItFInojERmaQoG","date":"Nov 30, 2022","link":"https://www.prnewswire.com/news-releases/nectin-therapeutics-announces-extended-series-a-financing-to-over-25m-and-initiation-of-patient-dosing-in-phase-1-clinical-trial-of-ntx1088-first-in-class-anti-pvr-targeted-immunotherapy-for-treatment-of-patients-with-advanced-s-301690195.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["clinical trial","investment","immunotherapies","biotechnology"],"company":"Nectin Therapeutics Ltd.","layoffs":null,"summary":"Nectin Therapeutics has announced the dosing of the first patient in its Phase 1 clinical trial of NTX1088, a first-in-class PVR (CD155) blocker for cancer patients with advanced solid tumors. The trial is being conducted at MD Anderson Cancer Center with an investment from the Cancer Focus Fund. Nectin has also extended its Series A financing to over $25 million, with IBF and Peregrine Ventures leading the round. The funding will be used to support the ongoing clinical evaluation of NTX1088 and advance the companys pipeline of targeted immunotherapies and Antibody Drug Conjugates (ADCs). NTX1088 aims to restore DNAM-1 expression on immune cells and stimulate an anti-tumor immune response. PVR is overexpressed in many solid tumors and is associated with resistance to PD-1 and PD-L1 blockade. The Phase 1 trial will include up to 90 patients treated with NTX1088 as a monotherapy and in combination with a PD-1 blocker.","partners":null,"customers":null,"investors":"Israel Biotech Fund (IBF), Peregrine Ventures, aMoon Fund, and other existing investors","confidence":8,"key_topics":["Phase 1 clinical trial","NTX1088","PVR blockade","immuno-oncology","funding"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Gkwh4P9ZtFsPNbsWBbEq9djbi3ZLlNkmQhEkJdljADMFFRsjofJG5H","news_summary":"Nectin Therapeutics Announces Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0a83ccfa-9484-4f65-a9cf-09eb8a9b27e7","date":"Mar 7, 2022","link":"https://www.prnewswire.com/il/news-releases/nectin-therapeutics-announces-5-4-million-investment-from-cancer-focus-fund-to-support-phase-1-study-of-first-in-class-anti-pvr-targeted-immunotherapy-301496469.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"investment","company":"Nectin Therapeutics Ltd.","layoffs":null,"summary":"Nectin Therapeutics and Cancer Focus Fund have announced a $5.4 million investment to finance a Phase 1 clinical trial of Nectins PVR blocker, NTX1088, in cancer patients with locally advanced and metastatic solid tumors. NTX1088 is a monoclonal antibody that blocks the signaling of immune checkpoint receptors, resulting in increased anti-tumor immune effects. The investment will support the clinical study at MD Anderson, and Cancer Focus Fund will receive equity and future payments based on certain milestones. The Phase 1 trial is expected to begin enrolling patients in mid-2022.","partners":null,"customers":null,"investors":"Cancer Focus Fund","confidence":9,"key_topics":["Nectin Therapeutics","Cancer Focus Fund","NTX1088","Phase 1 clinical trial","PVR blocker"],"date_of_event":"March 7, 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$5.4 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"mdQ1agXkM4EQXMbWTsJXDIh2A2MqE09Ku3x6RHp2uHBROrOG8U7Znb","news_summary":"Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8794e644-6af2-420c-beac-938617422c21","date":"Jul 14, 2020","link":"https://en.globes.co.il/en/article-amoon-invests-in-immuno-oncology-antibodies-co-nectin-1001335821","source":"en.globes.co.il","visible":1,"analysis":{"tags":"immuno-oncology, antibodies","company":"Nectin Therapeutics","layoffs":null,"summary":"Nectin Therapeutics, an Israeli immuno-oncology biotherapies company, has completed the first $6 million closing of a financing round led by aMoon Velocity and with the participation of Integra Holdings. The company plans to raise a total of $15 million in the financing round. Nectin Therapeutics develops antibodies that inhibit the activity of Nectin family proteins, enhancing the immune systems ability to fight cancers. The investment in Nectin Therapeutics aims to advance and improve the potential of novel immuno-oncology antibodies.","partners":null,"customers":null,"investors":"aMoon Velocity, Integra Holdings","confidence":9,"key_topics":["Nectin Therapeutics","antibodies","cancer treatment","immunotherapy","investment"],"date_of_event":"July 14, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$6 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"5mxTh6JTXDKSSgHmwfEswTpSEC1hHn3NuIbbBeav47yeRuu0YGIcr4","news_summary":"Israeli immuno-oncology co Nectin raises $6m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":7,"techcommunityinvolvement":null,"mediagallery":[{"id":"p3FFYC250sX4V6UZdEzZtb16DLPc6GOIYiLQOiYUeLZtzfSs0swVbo","timestamp":"2023-07-27 14:41:35.000000","resources_type":2,"resources_title":"","resources_file_name":"OIw17uQFz0A","alt":"","imageurl":"https://img.youtube.com/vi/OIw17uQFz0A/0.jpg","url":"http://youtu.be/OIw17uQFz0A"}],"tags":["biotechnology","pharmaceuticals","oncology","immunology","cancer-therapy","cancer","antibodies","patients","drug-delivery","treatments"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":[{"date":"2017-03-01","name":"Novel monoclonal antibodies for the treatment of solid and hematological malignancies.","tags":["cancer"],"category":"Life Sciences & Biotechnology","tto_logo":"/image_cloud/yissum_tto_logo_0151a5c5-6017-11e8-b269-41fdcbb0dda6","university_logo":"/image_cloud/yissum_institution_logo_0151a5c5-6017-11e8-b269-41fdcbb0dda6"}],"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["NTX2R13","NTX1088","ADC CANDIDATES"],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":7,"lastfunding":"$10M","totalrounds":6,"fundingstage":"A","totalfunding":"$36M","publicinvestors":7,"lastpublicfunding":10000000,"totalpublicrounds":6,"totalpublicfunding":36000000},"team":[{"name":"Fabian  Tenenbaum","email":"ftenenbaum@nectintx.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAkLS0sI8JDA","bounced":true,"claimed":0,"founder":0,"urlname":"fabian-tenenbaum","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICQ1OLugAoM","position":"CEO","last_name":" Tenenbaum","claimtoken":"BfYJ6y03grsn0mDF6EzTLL4b4aMhHRCZ3pLsdtaV7rjsJbzujkKXMk","first_name":"Fabian","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/fabian-tenenbaum/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-07-27 14:42:19.000000","initials":"F ","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Ofer  Mandelboim","email":"oferm@ekmd.huji.ac.il","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNnLiMoKDA","bounced":false,"claimed":0,"founder":1,"urlname":"ofer-mandelboim-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg-fbssAkM","position":"Co-founder","last_name":"Mandelboim","claimtoken":"FTY4vjX4CPNcGPvSkt3qT9pfvP6AzjE7TgsjFNgKfOhTDLyv8cFVJM","first_name":"Ofer ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/ofer-mandelboim-2848795b/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-05-06 13:36:43.000000","initials":"OM","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Pini Tsukerman","email":"pini@nectintx.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNmtidsJDA","bounced":false,"claimed":0,"founder":1,"urlname":"pini-tsukerman","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICguY-v0gkM","position":"Co-founder & CSO","last_name":"Tsukerman","claimtoken":"XEYksPjHOufArnLq7J6oTEWH42H3PdrgIVMG3zR7owNOwumIHj4vOa","first_name":"Pini","picturekey":"$dZJVydZ9dhO1FiaPpXTfk6bkQnrXeSgo5cyOqYUnYD9Zze5tMCXwUX","claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/emilyhastings-086432","unsubscribed":false,"is_activeuser":1,"additionalemail":"pinizuk@gmail.com","claimedemaildate":"2024-07-09 12:22:33.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$dZJVydZ9dhO1FiaPpXTfk6bkQnrXeSgo5cyOqYUnYD9Zze5tMCXwUX","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Keren  Paz","email":"keren.paz@nectintx.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAkJTW59EKDA","bounced":true,"claimed":0,"founder":0,"urlname":"keren-paz","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICQ1IHOhwoM","position":"Chief Development Officer","last_name":"Paz","claimtoken":"RDFJqHICF63bCVgnJwE6uQYqBvaibNl7uHJuhre3dpkanSlTll0ByY","first_name":"Keren ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/keren-paz-ab9940137/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-05-06 13:36:36.000000","initials":"KP","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Guy Cinamon","email":"guy.cinamon@nectintx.com","phone":"0544247524","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNnL7LsIDA","bounced":false,"claimed":0,"founder":0,"urlname":"guy-cinamon-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg2fr_xQoM","position":"VP R&D","last_name":"Cinamon","claimtoken":"MTFNjMPVcVHpqXJfAL9o3aLEOAqyQRNGex0yl7wQeuJe1F79QCOqEO","first_name":"Guy","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/guy-cinamon-2471493b/","unsubscribed":false,"is_activeuser":1,"additionalemail":"guy.cinamon@gmail.com","claimedemaildate":"2024-05-06 13:36:48.000000","initials":"GC","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoPW8rMQKDA","fullname":"Lena Rogovina"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMHXnNsIDA","fullname":"Jenny Sotnik-Talisman"},"biverifydate":"2020-04-07T00:00:00.000Z","crunchbaseid":"nectin-therapeutics","lastupdator":"Matan Eblagon","lastupdator_email":"matane@sncentral.org","creator":"Yotam Maman","creator_email":"yotamm1988@gmail.com","createdate":"2018-06-21T00:00:00.000Z","biverification":"Jenny Sotnik-Talisman","sectorverification":"Lena Rogovina","affiliatedOrganizations":null,"timeline":[{"id":"9ln1j1Q3T11FG9I4H6qzQeg5cUWtaFBHhITwqMuphH6UB3Qu0hm2vv","date":"May 2024","amount":"$10M","source":"https://en.globes.co.il/en/article-israeli-biotech-co-nectin-therapeutics-raises-10m-1001478040","eventtype":"FundingRoundEvent","investment":[{"name":"Guangzhou Sino-Israel Biotech Investment Fund (GIBF)","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/guangzhou-sino-israel-biotech-investment-fund-gibf","logokey":"$EhT54op1KN0bFQNfuNUIQuiaUEJvmdfmQuYVDy8ZGOHTKVos9xOEZg","tagline":null,"urlname":"/investor_page/guangzhou-sino-israel-biotech-investment-fund-gibf","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Nf6pOwIDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"iSJC0dPs3BgTohorHC0ojzoaMDeGjjRBquPFr6lDtI7KLoANaByDzy","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$EhT54op1KN0bFQNfuNUIQuiaUEJvmdfmQuYVDy8ZGOHTKVos9xOEZg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":10000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"xFAWk7GeHMd1qEH4asgKBruo3iqnGLJS1utY6UifkAUf6Y4BADv75Y","date":"May 2023","amount":"Undisclosed","source":"https://www.myelomainvestmentfund.org/portfolio/","eventtype":"FundingRoundEvent","investment":[{"name":"Myeloma Investment Fund","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/myeloma-investment-fund","logokey":"$G7LqY0WiPflKcjOt2VGuXhVFB7H3Ugmo0nzsSKN6tsnf0Pbd4HcGUI","tagline":"Self-sustaining venture fund","urlname":"/investor_page/myeloma-investment-fund","isisraeli":0,"investorid":"cqLhOeYX2AYjji4lco7TSk1TtX4EGHIv56VufksGNly6VKbaUzsUqB","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"nZ89oOuIl2HehzM5HmIcpuQ3VjMWJIeJdx7bxemmLxwKzzhB84qYxE","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$G7LqY0WiPflKcjOt2VGuXhVFB7H3Ugmo0nzsSKN6tsnf0Pbd4HcGUI","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"iuSPMzwBqx7mida61XBDfTYvN40tNFgwtZ9QgRJALeQW294KF9xMSl","date":"Dec 2022","amount":"$13.6M","source":"https://en.globes.co.il/en/article-israeli-co-nectin-therapeutics-raises-25m-1001431433","eventtype":"FundingRoundEvent","investment":[{"name":"Peregrine Ventures","type":"Investor","amount":1230000,"hidden":false,"country":"Israel","fullurl":"/investor_page/peregrine-ventures","logokey":"$T9b3MhmeKbyWXOhmHsdeo59IpRH5j3rFLwfog4x6rVvePI0vqruN3t","tagline":null,"urlname":"/investor_page/peregrine-ventures","isisraeli":1,"investorid":"Y57DaSxuoKU94wasDhLnfv7mvfy2Gyr9ekuOlM6BCGtWak5CprFY2M","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"KssztgjPBCFKj7ZpBbwKef4Ah07GR2Bfmu7sbg82LgODzswpzHfnHV","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$T9b3MhmeKbyWXOhmHsdeo59IpRH5j3rFLwfog4x6rVvePI0vqruN3t","leadcaption":"Lead ","followupcaption":""},{"name":"Israel Biotech Fund","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/israel-biotech-fund","logokey":"$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","tagline":null,"urlname":"/investor_page/israel-biotech-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwPKL6cUKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"g3wq4Ebhf2qd94iKFOse18M6EaW15zNczrla51eCl8vfa6ssURisxQ","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","leadcaption":"Lead ","followupcaption":""},{"name":"aMoon Fund","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/amoon-partners","logokey":"$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","tagline":null,"urlname":"/investor_page/amoon-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIj37p8KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"kQDG7qTraBT9PCd5Ao55BhOY0t3qvqBFyVTwpzciHCZLiDhkuj1hsc","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":13600000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJC01JmqCww","date":"Mar 2022","amount":"$5.4M","source":"https://www.prnewswire.com/il/news-releases/nectin-therapeutics-announces-5-4-million-investment-from-cancer-focus-fund-to-support-phase-1-study-of-first-in-class-anti-pvr-targeted-immunotherapy-301496469.html","eventtype":"FundingRoundEvent","investment":[{"name":"Cancer Focus Fund","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/cancer-focus-fund","logokey":"$U3XnAtfHxeEx6JP58WeN8sYScL6XG6zT4fk3fazjrSAkQ71uBCna26","tagline":"","urlname":"/investor_page/cancer-focus-fund","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODX-pmpCAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"WPmz1uL4Jt6fkud8RGIDRnETy4vOQLj0AKlK06V7K9WD40IVolFb5r","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$U3XnAtfHxeEx6JP58WeN8sYScL6XG6zT4fk3fazjrSAkQ71uBCna26","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5400000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOChlqPdCww","date":"Jul 2020","amount":"$6M","source":"https://en.globes.co.il/en/article-amoon-invests-in-immuno-oncology-antibodies-co-nectin-1001335821","eventtype":"FundingRoundEvent","investment":[{"name":"aMoon Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/amoon-partners","logokey":"$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","tagline":null,"urlname":"/investor_page/amoon-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIj37p8KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"e2bfb9c7-ee09-45a6-bec5-e20c15b3f64c","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","leadcaption":"Lead ","followupcaption":""},{"name":"Integra Holdings","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/integra-holdings","logokey":"$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","tagline":null,"urlname":"/investor_page/integra-holdings","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwNfNo5oLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"550ec0f2-253f-48e2-ab4f-d3a63002c703","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":6000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEzebECAw","date":"Jan 2017","amount":"$1M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Integra Holdings","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/integra-holdings","logokey":"$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","tagline":null,"urlname":"/investor_page/integra-holdings","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwNfNo5oLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"0062e660-ddf8-40bf-9055-6de220a47258","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":1000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"0pl7o9GMSB7uFvnq48VF3ibtSIh4iVXDWxLGdUwDmOstjuW0I0Qc13","hub":"BioGiv","date":"","batch":"","amount":"Undisclosed","hub_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4NyEhJIKDA","source":"","enddate":"","hub_type":"Entrepreneurship Program","eventtype":"GraduationEvent","hub_hidden":false,"investment":[],"hub_fullurl":"/program_page/biogiv","hub_logokey":"$s6g12I1QNPxaMzuKNWZSQjc4FOWLALyqm22Yc3vZTNkPsRlmvrNqM0","hub_urlname":"/program_page/biogiv","eventvisibility":null,"amountvisibility":null,"fundingvisibility":null,"style":"","hiddenCompanyTooltip":"","hub_logourl":"https://storage.googleapis.com/clean-finder-353810/$s6g12I1QNPxaMzuKNWZSQjc4FOWLALyqm22Yc3vZTNkPsRlmvrNqM0","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"1/2017","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Nectin Therapeutics","logourl":"https://storage.googleapis.com/clean-finder-353810/$qORXS8Vu1j2wfNA0DNbcalolIMwmIFNm8GSboiCTN6S5MF5pnyzjZA.jpeg","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$qORXS8Vu1j2wfNA0DNbcalolIMwmIFNm8GSboiCTN6S5MF5pnyzjZA.jpeg","seoabout":"Nectin Therapeutics is a biotechnology company devoted to transforming the lives of cancer patients by the development of next-generation immune-oncology (...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":5,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Patients","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"}]},{"title":"Life Sciences","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Cells","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Cells"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Cells"],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Patients","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"9ln1j1Q3T11FG9I4H6qzQeg5cUWtaFBHhITwqMuphH6UB3Qu0hm2vv","date":"May 2024","amount":"$10M","source":"https://en.globes.co.il/en/article-israeli-biotech-co-nectin-therapeutics-raises-10m-1001478040","eventtype":"FundingRoundEvent","investment":[{"name":"Guangzhou Sino-Israel Biotech Investment Fund (GIBF)","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/guangzhou-sino-israel-biotech-investment-fund-gibf","logokey":"$EhT54op1KN0bFQNfuNUIQuiaUEJvmdfmQuYVDy8ZGOHTKVos9xOEZg","tagline":null,"urlname":"/investor_page/guangzhou-sino-israel-biotech-investment-fund-gibf","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Nf6pOwIDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"iSJC0dPs3BgTohorHC0ojzoaMDeGjjRBquPFr6lDtI7KLoANaByDzy","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$EhT54op1KN0bFQNfuNUIQuiaUEJvmdfmQuYVDy8ZGOHTKVos9xOEZg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":10000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"xFAWk7GeHMd1qEH4asgKBruo3iqnGLJS1utY6UifkAUf6Y4BADv75Y","date":"May 2023","amount":"Undisclosed","source":"https://www.myelomainvestmentfund.org/portfolio/","eventtype":"FundingRoundEvent","investment":[{"name":"Myeloma Investment Fund","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/myeloma-investment-fund","logokey":"$G7LqY0WiPflKcjOt2VGuXhVFB7H3Ugmo0nzsSKN6tsnf0Pbd4HcGUI","tagline":"Self-sustaining venture fund","urlname":"/investor_page/myeloma-investment-fund","isisraeli":0,"investorid":"cqLhOeYX2AYjji4lco7TSk1TtX4EGHIv56VufksGNly6VKbaUzsUqB","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"nZ89oOuIl2HehzM5HmIcpuQ3VjMWJIeJdx7bxemmLxwKzzhB84qYxE","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$G7LqY0WiPflKcjOt2VGuXhVFB7H3Ugmo0nzsSKN6tsnf0Pbd4HcGUI","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"iuSPMzwBqx7mida61XBDfTYvN40tNFgwtZ9QgRJALeQW294KF9xMSl","date":"Dec 2022","amount":"$13.6M","source":"https://en.globes.co.il/en/article-israeli-co-nectin-therapeutics-raises-25m-1001431433","eventtype":"FundingRoundEvent","investment":[{"name":"Peregrine Ventures","type":"Investor","amount":1230000,"hidden":false,"country":"Israel","fullurl":"/investor_page/peregrine-ventures","logokey":"$T9b3MhmeKbyWXOhmHsdeo59IpRH5j3rFLwfog4x6rVvePI0vqruN3t","tagline":null,"urlname":"/investor_page/peregrine-ventures","isisraeli":1,"investorid":"Y57DaSxuoKU94wasDhLnfv7mvfy2Gyr9ekuOlM6BCGtWak5CprFY2M","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"KssztgjPBCFKj7ZpBbwKef4Ah07GR2Bfmu7sbg82LgODzswpzHfnHV","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$T9b3MhmeKbyWXOhmHsdeo59IpRH5j3rFLwfog4x6rVvePI0vqruN3t","leadcaption":"Lead ","followupcaption":""},{"name":"Israel Biotech Fund","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/israel-biotech-fund","logokey":"$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","tagline":null,"urlname":"/investor_page/israel-biotech-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwPKL6cUKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"g3wq4Ebhf2qd94iKFOse18M6EaW15zNczrla51eCl8vfa6ssURisxQ","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","leadcaption":"Lead ","followupcaption":""},{"name":"aMoon Fund","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/amoon-partners","logokey":"$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","tagline":null,"urlname":"/investor_page/amoon-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIj37p8KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"kQDG7qTraBT9PCd5Ao55BhOY0t3qvqBFyVTwpzciHCZLiDhkuj1hsc","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":13600000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJC01JmqCww","date":"Mar 2022","amount":"$5.4M","source":"https://www.prnewswire.com/il/news-releases/nectin-therapeutics-announces-5-4-million-investment-from-cancer-focus-fund-to-support-phase-1-study-of-first-in-class-anti-pvr-targeted-immunotherapy-301496469.html","eventtype":"FundingRoundEvent","investment":[{"name":"Cancer Focus Fund","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/cancer-focus-fund","logokey":"$U3XnAtfHxeEx6JP58WeN8sYScL6XG6zT4fk3fazjrSAkQ71uBCna26","tagline":"","urlname":"/investor_page/cancer-focus-fund","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODX-pmpCAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"WPmz1uL4Jt6fkud8RGIDRnETy4vOQLj0AKlK06V7K9WD40IVolFb5r","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$U3XnAtfHxeEx6JP58WeN8sYScL6XG6zT4fk3fazjrSAkQ71uBCna26","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5400000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOChlqPdCww","date":"Jul 2020","amount":"$6M","source":"https://en.globes.co.il/en/article-amoon-invests-in-immuno-oncology-antibodies-co-nectin-1001335821","eventtype":"FundingRoundEvent","investment":[{"name":"aMoon Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/amoon-partners","logokey":"$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","tagline":null,"urlname":"/investor_page/amoon-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIj37p8KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"e2bfb9c7-ee09-45a6-bec5-e20c15b3f64c","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","leadcaption":"Lead ","followupcaption":""},{"name":"Integra Holdings","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/integra-holdings","logokey":"$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","tagline":null,"urlname":"/investor_page/integra-holdings","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwNfNo5oLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"550ec0f2-253f-48e2-ab4f-d3a63002c703","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":6000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEzebECAw","date":"Jan 2017","amount":"$1M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Integra Holdings","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/integra-holdings","logokey":"$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","tagline":null,"urlname":"/investor_page/integra-holdings","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwNfNo5oLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"0062e660-ddf8-40bf-9055-6de220a47258","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":1000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}